Observational studyBlood advances2025

TRANSCAR: real-world outcomes of CD19 CAR T-cell therapy in relapsed/refractory transformed indolent lymphomas.

Pierre Stephan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.